Benign prostatic hyperplasia and male lower urinary symptoms:A guide for family physicians
Farhad Fakhrudin Vasanwalaa, Michael Yuet Chen Wongb, Henry Sun Sien Hoc, Keong Tatt Fooc
a Department of Family Medicine, Sengkang Hospital at Alexandra Hospital, SingHealth, Singapore; b International Urology, Fertility and Gynaecology Centre, Mount Elizabeth Medical Centre, Singapore; c Department of Urology, Singapore General Hospital, SingHealth, Singapore
Benign prostatic hyperplasia and male lower urinary symptoms:A guide for family physicians
Farhad Fakhrudin Vasanwalaa, Michael Yuet Chen Wongb, Henry Sun Sien Hoc, Keong Tatt Fooc
a Department of Family Medicine, Sengkang Hospital at Alexandra Hospital, SingHealth, Singapore; b International Urology, Fertility and Gynaecology Centre, Mount Elizabeth Medical Centre, Singapore; c Department of Urology, Singapore General Hospital, SingHealth, Singapore
摘要 Male patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are increasingly seen by family physicians worldwide due to ageing demographics. A systematic way to stratify patients who can be managed in the community and those who need to be referred to the urologist is thus very useful. Good history taking, physical examination, targeted blood or urine tests, and knowing the red flags for referral are the mainstay of stratifying these patients. Case selection is always key in clinical practice and in the setting of the family physician. The best patient to manage is one above 40 years of age, symptomatic with nocturia, slower stream and sensation of incomplete voiding, has a normal prostatespecific antigen level, no palpable bladder, and no haematuria or pyuria on the labstix. The roles of α blockers, 5-α reductase inhibitors, and antibiotics in a primary care setting to manage this condition are also discussed.
Abstract: Male patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are increasingly seen by family physicians worldwide due to ageing demographics. A systematic way to stratify patients who can be managed in the community and those who need to be referred to the urologist is thus very useful. Good history taking, physical examination, targeted blood or urine tests, and knowing the red flags for referral are the mainstay of stratifying these patients. Case selection is always key in clinical practice and in the setting of the family physician. The best patient to manage is one above 40 years of age, symptomatic with nocturia, slower stream and sensation of incomplete voiding, has a normal prostatespecific antigen level, no palpable bladder, and no haematuria or pyuria on the labstix. The roles of α blockers, 5-α reductase inhibitors, and antibiotics in a primary care setting to manage this condition are also discussed.
Farhad Fakhrudin Vasanwala, Michael Yuet Chen Wong, Henry Sun Sien Ho, Keong Tatt Foo. Benign prostatic hyperplasia and male lower urinary symptoms:A guide for family physicians[J]. Asian Journal of Urology, 2017, 4(3): 181-184.
Farhad Fakhrudin Vasanwala, Michael Yuet Chen Wong, Henry Sun Sien Ho, Keong Tatt Foo. Benign prostatic hyperplasia and male lower urinary symptoms:A guide for family physicians. Asian Journal of Urology, 2017, 4(3): 181-184.
[1] Luo GC, Foo KT, Kuo T, Tan G. Diagnosis of prostate adenoma and the relationship between the site of prostate adenoma and bladder outlet obstruction. Singap Med J 2013;54:482-6. [2] Australia and New Zealand Urological Nurses Society Inc. Management of male lower urinary tract symptoms (LUTS) and clinical practice guidelines. 2010. https://view.officeapps.live.com/op/view.aspx?srcZhttp%3A%2F%2Fwww.anzuns.org%2FLUTS_guidelines_Urology_NP_updated_Jan_2010-2.DOC[Accessed 14 February 2017]. [3] Ngui M. An update:BPH management for family physicians. 2010. http://thischangedmypractice.com/an-update-bphmanagement-for-family-physicians[Accessed 14 February 2017]. [4] Nitti VW. Urodynamic and videourodynamic evaluation of the lower urinary tract. In:Wein AJ, editor. Campbell-Walsh urology. 10th ed. Philadelphia, PA:Elsevier Saunders; 2011. Chapter 66. [5] Winters JC, Dmochowski RR, Goldman HB, Herndon CDA, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults:AUA/SUFU guideline. J Urol 2012;188(6 Suppl):2464-72. [6] Latil A, Pétrissans MT, Rouquet J, Robert G, de la Taille A. Effects of hexanic extract of serenoa repens (Permixon 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate 2015;75:1857-67. [7] Kappor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol 2012;19(Suppl 1):10-7. [8] Barkin J. Management of benign prostatic hyperplasia by the primary care physician in the 21st century:the new paradigm. Can J Urol 2008;15(Suppl 1):21-30. [9] Wong MYC. Family physician guide to urology. Edition 2. Singapore:Department of Urology, Singapore General Hospital; 2001. p. 56e8.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
